At our Meet Novartis Management event for investors and analysts today in London, we announced that we rolled forward mid-term guidance and highlighted our robust pipeline to drive sustainable growth. With a strong portfolio, we upgraded sales guidance for key growth drivers, expect 15+ potential submission-enabling readouts over the next two years and have more than 30 high-value medicines in our pipeline. Learn more about our outlook here: https://lnkd.in/gqrffTgH #NovartisNews $NVS $NOVN #ReimaginingMedicine
I still don't understand why it was deleted. Why, really, why?! Can't you look at this child with compassion?! Can't you hear the cry of a father who wants nothing but the kindness of parents from an administration that is itself comprised of fathers and mothers?My child cries out to you for fatherhood, mercy, and compassion with every breath she takes. Is it truly impossible for her to find anyone to answer her, when you know she has no recourse after God but you. #save_basmalah Novartis
This is amazing
Strong outlook from Novartis! A +5–6% cc CAGR and 30+ high-value pipeline assets signal a solid path toward next-gen launches. As a recently graduated formulation engineer, I’m keen to see how this growth translates into upstream formulation and scale-up innovation.
great
Looks like an active roadmap for the next couple of years. Curious to see which programs move forward
Novartis’ upgraded mid-term guidance, backed by 30+ high-value medicines and 15+ near-term readouts, reflects focus on both momentum and resilience.
Great work! ✨
VP, Industry Strategy @ Siemens DI SW | Digital Transformation
21hStrong outlook from Novartis with the 15+ readouts and the 30+ medicines. The clarity on 5–6% CAGR and 40%+ margins gives investors a clean view of the path ahead.